Početna stranicaMRCK34 • BVMF
add
Merck & Co.
Preth. zaklj. cijena
76,14 R$
Dnevni raspon
74,15 R$ - 76,14 R$
Godišnji raspon
60,19 R$ - 94,00 R$
Tržišna kapitalizacija
254,59 mlr. USD
Prosječna količina
6,13 tis.
U vijestima
Financijski podaci
Račun dobiti i gubitka
Prihod
Neto dohodak
| (USD) | ruj 2024.info | Godišnja promjena |
|---|---|---|
Prihod | 16,66 mlr. | 4,35 % |
Operativni troškovi | 8,40 mlr. | 48,81 % |
Neto dohodak | 3,16 mlr. | −33,47 % |
Neto profitabilnost | 18,95 | −36,26 % |
Zarada po dionici | 1,57 | −26,29 % |
EBITDA | 5,51 mlr. | −21,97 % |
Efektivna porezna stopa | 22,71 % | — |
Bilanca stanja
Ukupna imovina
Ukupne obveze
| (USD) | ruj 2024.info | Godišnja promjena |
|---|---|---|
Gotovinska i kratkoročna ulaganja | 14,59 mlr. | 66,34 % |
Ukupna imovina | 117,53 mlr. | 10,12 % |
Ukupne obveze | 72,97 mlr. | 11,53 % |
Ukupni kapital | 44,56 mlr. | — |
Dionice u optjecaju | 2,53 mlr. | — |
Cijena prema knjigovodstvenoj vrijednosti | 4,33 | — |
Povrat imovine | 9,48 % | — |
Povrat kapitala | 13,29 % | — |
Tok novca
Neto promjena novca
| (USD) | ruj 2024.info | Godišnja promjena |
|---|---|---|
Neto dohodak | 3,16 mlr. | −33,47 % |
Gotovina od poslovanja | 9,29 mlr. | 20,40 % |
Gotovina iz ulaganja | −3,84 mlr. | −1.051,20 % |
Gotovina iz financiranja | −2,42 mlr. | 43,20 % |
Neto promjena novca | 3,32 mlr. | 12,11 % |
Slobodan tok novca | 7,42 mlr. | 28,97 % |
Više
Merck & Co., Inc. is an American multinational pharmaceutical company headquartered in Rahway, New Jersey, and is named for Merck Group, founded in Germany in 1668, of which it was once the American arm. The company does business as Merck Sharp & Dohme or MSD outside the United States and Canada. It is one of the largest pharmaceutical companies in the world, generally ranking in the global top five by revenue.
Merck & Co. was originally established as the American affiliate of Merck Group in 1891. Merck develops and produces medicines, vaccines, biologic therapies and animal health products. It has several blockbuster products, including cancer immunotherapy, anti-diabetic medications, and vaccines for HPV and chickenpox, each generating significant revenue as of 2020.
The company is ranked 71st on the 2022 Fortune 500 and 87th on the 2022 Forbes Global 2000, both based on 2021 revenues. In 2023, the company’s seat in Forbes Global 2000 was 73. Wikipedia
Glavni izvršni direktor
Osnovano
1. sij 1891.
Web-lokacija
Zaposlenici
71.000
